<DOC>
	<DOC>NCT00191555</DOC>
	<brief_summary>The objective of this study is to demonstrate that there is a benefit in switching chronic schizophrenic patients from conventional antipsychotic to olanzapine in terms of efficacy, neurological safety and patient's outcome.</brief_summary>
	<brief_title>Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Schizophrenic patient meeting the DSMIV diagnostic criteria more than one year ago and treated with antipsychotic for at least 1 year. Outpatient (or patient admitted to hospital for social or logistic reasons). Patient receiving a stable dose of the same conventional antipsychotic for at least 8 weeks before visit 1. Patient presenting a PANSS score equal or greater than 49 at Visit 2. Patient considered by the investigator as possible candidates for a switch, owing to inadequate efficacy or poor safety of the current treatment. Patient presenting a schizophreniform or a schizoaffective disorder according to the DSMIV diagnostic criteria, or any other disorder from Axis I of the DSMIV, or a disorder from Axis II (limit personality), substance dependence or substance abuse. Administration of an atypical antipsychotic drug during the 8 weeks preceding V1. History of resistance to antipsychotic drugs Hospitalization in a psychiatric unit or in a psychiatric emergency department within the 8 weeks preceding the beginning of the study. Presence of serious unstable disease, such as a fatal outcome or hospitalization in an intensive care unit, is foreseeable within a period of 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>